Narendra Bagri | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Assoc. Prof. Dr. Narendra Bagri | Clinical Trials | Best Researcher Award

All India Institute of Medical Sciences | India

Assoc. Prof. Dr. Narendra Bagri is a distinguished clinician and academician in the field of pediatric rheumatology, presently serving as Additional Professor in the Department of Pediatrics, Division of Pediatric Rheumatology at the All India Institute of Medical Sciences (AIIMS), New Delhi, India. A graduate and postgraduate of the Institute of Medical Sciences, Banaras Hindu University, he has built a remarkable career through a blend of clinical excellence, teaching, and groundbreaking research in pediatric autoimmune and inflammatory disorders. He completed the prestigious PRES EMERGE Fellowship in Pediatric Rheumatology at the Bristol Royal Hospital for Children, UK, under the mentorship of Prof. A.V. Ramanan, enhancing his expertise in advanced pediatric rheumatologic care and translational research.Dr. Bagri’s scientific contributions encompass numerous impactful publications addressing critical aspects of pediatric inflammatory diseases, musculoskeletal imaging, and immunological mechanisms underlying juvenile idiopathic arthritis. His research includes the longitudinal analysis of multisystem inflammatory syndrome in children temporally related to COVID-19, the evaluation of pulse dexamethasone therapy in non-systemic juvenile idiopathic arthritis, and the technical and interpretive insights into pediatric musculoskeletal ultrasound. He has also authored work on the utility of musculoskeletal ultrasound in juvenile idiopathic arthritis, the forgotten figure in the history of methotrexate, sympathetic blocks for Raynaud’s phenomena in pediatric rheumatological disorders, and the conception of a national biologics registry for pediatric rheumatology.As a principal investigator and collaborator in multiple funded research projects by the Indian Council of Medical Research (ICMR) and the Science and Engineering Research Board (SERB), Dr. Bagri has contributed extensively to the understanding of synovial fluid proteomics, biomarker discovery, and immune-pathogenic mechanisms in childhood arthritis. His pioneering efforts include the development of transitional care services, collaborative rheumatology clinics, and the initiation of diagnostic and therapeutic procedures such as ultrasound-guided intra-articular injections and synovial biopsies.Dr. Bagri is a life member of several professional bodies, including the Indian Rheumatology Association, the Pediatric Rheumatology European Society, and the Indian Academy of Pediatrics. Recognized for his outstanding contributions, he has received multiple academic honors, travel grants, and leadership roles in national guideline formulation, including contributions to WHO and IAP documents on pediatric inflammatory syndromes. His dedication to research, patient care, and education continues to shape the evolution of pediatric rheumatology in India and beyond.

Profile: Google Scholar

Featured Publications

Bagri, N. K., Jose, B., Shah, S. K., Bhutia, T. D., Kabra, S. K., & Lodha, R. (n.d.). Impact of malnutrition on the outcome of critically ill children. The Indian Journal of Pediatrics, 82(7), 601–605.

Sivasubbu, S., & Scaria, V. (n.d.). Genomics of rare genetic diseases—experiences from India. Human Genomics.

Basu, S., Kumar, A., Kapoor, K., Bagri, N. K., & Chandra, A. (n.d.). Neonatal endogenous endophthalmitis: A report of six cases. Pediatrics.

Bagri, N., Saha, A., Chandelia, S., Dubey, N. K., Bhatt, A., Rai, A., & Bhattacharya, S. (n.d.). Fireworks injuries in children: A prospective study during the festival of lights. Emergency Medicine Australasia.

Bagri, N. K., Yadav, D. K., Agarwal, S., Aier, T., & Gupta, V. (n.d.). Pericardial effusion in children: Experience from tertiary care center in northern India. Indian Pediatrics.

Kumar, A., Bagri, N. K., Basu, S., & Asthana, R. K. (n.d.). Zinc supplementation for neonatal hyperbilirubinemia: A randomized controlled trial. Indian Pediatrics.

Bagri, N. K., Deepak, R. K., Meena, S., Gupta, S. K., Prakash, S., Setlur, K., Satapathy, J., Chopra, K., Upadhyay, A. D., Ramakrishnan, S., Lodha, R., Dar, L., Trikha, A., & Kabra, S. K. (n.d.). Outcomes of multisystem inflammatory syndrome in children temporally related to COVID-19: A longitudinal study. Rheumatology International.

Gupta, D., Thakral, D., Kumar, P., Kabra, S. K., Lodha, R., Kumari, R., Mohanty, S. K., … & Bagri, N. K. (n.d.). Primary immunodeficiency disorders among north Indian children. The Indian Journal of Pediatrics.

Elli Anna Kotsailidi | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Assist. Prof. Dr. Elli Anna Kotsailidi | Clinical Trials | Best Researcher Award

University of Rochester | United States

Assist. Prof. Dr. Elli Anna Kotsailidi is a distinguished academic and clinician specializing in periodontology, implant dentistry, and health professions education. She serves as an Assistant Professor of Clinical Dentistry at the University of Rochester, School of Medicine and Dentistry, and is a key faculty member at the Eastman Institute for Oral Health. With a strong foundation in dental surgery and advanced expertise in periodontal and implant sciences, she has built a remarkable career combining clinical excellence, academic leadership, and educational innovation.Dr. Kotsailidi’s academic journey began with her dental degree from the National and Kapodistrian University of Athens, where she demonstrated early dedication to clinical precision and scientific inquiry. Her pursuit of advanced specialization led her to the Eastman Institute for Oral Health at the University of Rochester, where she completed rigorous training in periodontology and implant dentistry, refining her skills in evidence-based patient care and complex surgical procedures. Further expanding her professional vision, she completed a master’s degree in Health Professions Education at the Warner School of Education, University of Rochester, focusing on curriculum development, equitable teaching, and the enhancement of academic excellence in dental education.Her professional career reflects an unwavering commitment to both patient-centered care and academic mentorship. As Program Director and former Clinic Director in the Department of Periodontology at the Eastman Institute for Oral Health, she has played a pivotal role in shaping clinical programs, overseeing resident training, and ensuring adherence to the highest standards of quality assurance and ethical practice. Her role integrates patient management, surgical supervision, curriculum coordination, and leadership in interdisciplinary dental education involving periodontics, prosthodontics, and general dentistry.Dr. Kotsailidi’s teaching philosophy is deeply rooted in inclusivity, collaboration, and innovation. She has co-directed and taught numerous courses, including Cell Biology of Disease, Introduction to Periodontology, Oral Implantology, ABP Mock Boards, and the Literature Review Series in Periodontics and Dental Implantology. Her approach emphasizes integrative learning, clinical reasoning, and the practical application of scientific knowledge in patient care. She is also an active mentor, serving on research committees for master’s students, guiding systematic reviews and meta-analyses that contribute to evidence-based dentistry and global oral health advancement.

Profile: Orcid

Featured Publications

Umbrio, L. R. N., Pham, H. M., Barmak, A. B., Assery, N., & Kotsailidi, E. A. (2025). Association between selective serotonin reuptake inhibitors and the periodontal status: A systematic review and meta-analysis of observational clinical studies. Evidence-Based Dentistry.

Benzaquen, S. I., Torabi Ardakani, M., Tsigarida, A., Ercoli, C., Barmak, B., Chochlidakis, K. M., & Kotsailidi, E. A. (2025). Biologic complications with removable partial dentures assisted by short implants: A 34-month pilot randomized controlled clinical trial. The Journal of Prosthetic Dentistry.

Kotsailidi, E. A., Johnson, L., Burns, C., Rossouw, P. E., & Michelogiannakis, D. (2025). Surgically facilitated orthodontics with clear aligners for severe malocclusion and gingival recessions. Clinical Advances in Periodontics.

Burns, C., Kotsailidi, E. A., Alshuraim, F., Dadjoo, S., Tzouma, K., Pedrinaci, I., Rossouw, P. E., & Michelogiannakis, D. (2024). Interdisciplinary orthodontic treatment with digitally-guided autotransplantation in a patient with a missing permanent maxillary left lateral incisor and a supernumerary mandibular incisor. AJO-DO Clinical Companion.

Shadi Hamoud | Clinical Trials | Excellence in Research Award

Published on by Top Pharmaceutical

Dr. Shadi Hamoud | Clinical Trials | Excellence in Research Award

Rambam health care campus | Israel

Dr. Shadi Hamoud is a distinguished physician, clinical researcher, and academic leader whose career spans internal medicine, cardiovascular research, and translational medicine. Earning his medical degree with honors from the Faculty of Medicine at the Hebrew University in Jerusalem, Dr. Hamoud embarked on a professional journey characterized by clinical excellence, research innovation, and a deep commitment to medical education. Over the years, he has combined patient-centered care with groundbreaking research, focusing on lipoprotein oxidation, atherosclerosis, the role of the enzyme heparanase in kidney injury, fatty liver disease, and cardiovascular disorders, as well as pioneering clinical trials for novel oral anticoagulants, lipid-modifying agents, diabetes treatments, and therapies for emerging infectious diseases such as COVID-19.As Deputy Director of the Department of Internal Medicine E at Rambam Medical Center and Director of the Clinical Research Unit, Dr. Hamoud has overseen numerous national and international clinical studies, collaborating with leading pharmaceutical companies, including Bayer, Pfizer, Novartis, Sanofi, and AstraZeneca. His research portfolio reflects expertise in designing and conducting complex multicenter clinical trials addressing some of the most challenging issues in cardiovascular medicine and metabolic diseases. Additionally, his clinical consultancy roles across multiple departments at Rambam Health Care Campus highlight his interdisciplinary approach to medicine, ensuring that research findings translate effectively into improved patient outcomes.An accomplished educator, Dr. Hamoud has dedicated decades to training the next generation of physicians, serving as a clinical lecturer at the Technion-Israel Institute of Technology and mentoring medical students, interns, and graduate researchers. Under his supervision, numerous MD and basic science theses have been completed, exploring critical areas such as oxidative stress, endothelial dysfunction, liver steatosis, and the molecular pathways of atherosclerosis. His leadership as Program Director for the Internal Medicine Preparatory Course for National Licensing Examinations further reflects his commitment to academic excellence and medical training standards.

Profile: Orcid

Featured Publications

Hamoud, S., Hacker, I., Karram, T., Fokra, A., Kabala, A., & Abassi, Z. (2024). Gender-specific renoprotective pathways in αMUPA transgenic mice subjected to acute kidney injury. International Journal of Molecular Sciences.

Cohen-Segev, R., Nativ, O., Kinaneh, S., Aronson, D., Kabala, A., Hamoud, S., Karram, T., & Abassi, Z. (2023). Effects of angiotensin 1-7 and Mas receptor agonist on renal system in a rat model of heart failure. International Journal of Molecular Sciences.

Kinaneh, S., Hijaze, W., Mansour-Wattad, L., Hammoud, R., Zaidani, H., Kabala, A., & Hamoud, S. (2022). Heparanase inhibition prevents liver steatosis in E₀ mice. Journal of Clinical Medicine.

[Author names not fully provided]. (n.d.). Predictors of survival in subjects treated in the “shock room” of the emergency department in a tertiary medical center.

Albert Eisenbarth | Clinical Trials | Best Scholar Award

Published on by Top Pharmaceutical

Dr. Albert Eisenbarth | Clinical Trials | Best Scholar Award

Entomologe at Bundeswehr Hospital Hamburg | Germany

Dr. Albert Eisenbarth is a biologist specializing in parasitology, vector biology, and emerging infectious diseases. He earned his doctorate at the University of Tübingen, focusing on Onchocerca ochengi and its relevance to river blindness epidemiology. His career spans international research assignments across Africa, Asia, and Europe, contributing to studies on vector-borne diseases, zoonotic pathogens, and host-parasite interactions. Dr. Eisenbarth has worked at prestigious institutions including the Friedrich Loeffler Institute for Animal Health and the University of Tübingen. With over a decade of field and laboratory expertise, his work bridges veterinary medicine, parasitology, and global health, advancing infectious disease control strategies.

Publication Profile 

Scopus

Education 

Dr. Albert Eisenbarth completed his MSc in Parasitology at the Institute of Tropical Medicine, University of Tübingen, where he conducted his thesis on anisakid nematodes in Australian waters. He pursued doctoral studies at the University of Tübingen, earning his Doctor of Biology degree with a thesis on the biology of Onchocerca ochengi and its epidemiological implications for river blindness. His academic training also included international research exchanges at the University of Melbourne, the Royal Melbourne Institute of Technology, the University of Cape Town, and Kasetsart University in Bangkok. His education combines parasitology, vector biology, and tropical infectious disease research.

Experience 

Dr. Albert Eisenbarth has held diverse research and professional roles. He served as a Research Fellow at the Friedrich Loeffler Institute for Animal Health, working on novel and emerging infectious diseases. Previously, he completed his doctoral and postdoctoral research at the University of Tübingen and in Cameroon within the Onchocerciasis Programme. His career includes positions as Clinical Data Manager at Kendle GmbH and scientific assistant roles at the University of Tübingen. He has undertaken extensive international assignments in Mozambique, Mauritania, Cameroon, Thailand, France, Australia, and South Africa. His expertise encompasses parasitology, vector ecology, epidemiology, and zoonotic disease transmission at the human-animal interface.

Awards and Honors 

Dr. Albert Eisenbarth has received multiple awards and grants for his scientific contributions. He co-coordinated major DFG-funded projects investigating zoonotic viral transmission, including Rift Valley Fever and Crimean-Congo Hemorrhagic Fever in Africa. As principal investigator, he secured a RiSC Young Scientist grant for research on genetic susceptibility to tick-borne diseases in African cattle. His international collaborations earned him a South East Asia–European Union NET II Fellowship, supporting One Health research. He has also been recognized with travel grants from the German Society for Parasitology and the Erwin Riesch Foundation. Additionally, he was awarded DAAD fellowships for both MSc and doctoral studies.

Research Focus 

Dr. Albert Eisenbarth research focuses on parasitology, vector-borne diseases, and zoonotic infections affecting both human and animal health. He has conducted extensive work on the epidemiology of Onchocerca volvulus and Onchocerca ochengi, contributing to onchocerciasis control strategies. His studies include the diversity, abundance, and pathogen carriage of hematophagous vectors such as mosquitoes and ticks in Africa. Additionally, he investigates emerging viral diseases, including Rift Valley Fever and Crimean-Congo Hemorrhagic Fever, across the livestock-wildlife-human interface. Through molecular and field-based approaches, his work integrates parasitology, virology, and epidemiology, providing valuable insights for global health, One Health initiatives, and disease elimination programs.

Publication Top Notes

Molecular detection of Leishmania (Sauroleishmania) adleri (Trypanosomatida: Trypanosomatidae) in Sergentomyia sp. sand flies (Diptera: Psychodidae) in Mali and Niger

Mosquito survey in Mauritania: Detection of Rift Valley fever virus and dengue virus and the determination of feeding patterns

Conclusion

Dr. Albert Eisenbarth possesses the academic excellence, research productivity, and global health relevance that make him a strong candidate for the Research for Best Scholar Award. His innovative studies on parasitic and vector-borne diseases, coupled with his ability to secure competitive grants and engage in international collaborations, demonstrate outstanding scholarly merit. With continued expansion into broader leadership and translational activities, he is well-positioned to further influence the fields of parasitology, epidemiology, and infectious disease research. His track record aligns with the award’s goal of recognizing impactful and forward-looking scientific scholarship.

Aiyin Chen | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Aiyin Chen | Clinical Trials | Best Researcher Award

Associate Professor at Oregon Health & Science University | United States

Dr. Aiyin Chen is an accomplished ophthalmologist and glaucoma specialist, recognized for her expertise in clinical care, research, and academic leadership. She serves as an Associate Professor in the Department of Ophthalmology at Oregon Health & Science University’s Casey Eye Institute. Dr. Chen’s career bridges advanced patient care with groundbreaking research in glaucoma detection, machine learning risk prediction, and optical coherence tomography applications. She has led and collaborated on multiple NIH-funded projects, contributed extensively to peer-reviewed literature, and worked to improve vision health in underserved populations. Dedicated to advancing ophthalmic science, Dr. Chen’s work continues to shape the future of glaucoma care.

Publication Profile 

Google Scholar

Education 

Dr. Aiyin Chen earned her Bachelor of Arts degree in Biological Sciences with a Neurobiology and Behavior concentration from Cornell University, graduating magna cum laude with distinction. She obtained her Doctor of Medicine with thesis distinction from the University of California, San Francisco (UCSF) School of Medicine. Following medical school, she completed a transitional internship at Atlantic Health Morristown Memorial Hospital and Mount Sinai School of Medicine. Dr. Chen then pursued ophthalmology residency training and a glaucoma fellowship at UCSF. She is certified by the American Board of Ophthalmology and holds active medical licenses in Oregon, Washington, and California, with prior licensure in Nevada.

Experience 

Dr. Aiyin Chen professional journey includes service as a glaucoma specialist at Wellish Vision Institute, and surgical roles at Sunrise Hospital and Box Canyon Surgery Center in Las Vegas. She transitioned to academia at the Casey Eye Institute, Oregon Health & Science University, where she served as Assistant Professor before advancing to Associate Professor. Her clinical expertise encompasses complex glaucoma management and surgery, while her administrative and teaching roles support training the next generation of ophthalmologists. Dr. Chen has been deeply involved in multi-institutional research collaborations, NIH-funded studies, and projects integrating telemedicine and big data analytics to improve glaucoma detection, diagnosis, and patient outcomes.

Awards and Honors 

Dr. Aiyin Chen has earned multiple distinctions throughout her academic and professional career, including thesis distinction during her MD program and recognition for her NIH-funded research contributions in ophthalmology. She has been selected as a K12 Clinical Scientist Institutional Career Development Awardee, underscoring her leadership in translational research. Her grant portfolio includes principal investigator and co-investigator roles on high-impact glaucoma studies funded by the National Eye Institute and National Library of Medicine. Dr. Chen’s scholarship, mentorship, and commitment to improving vision health in underserved communities have established her as a leader in ophthalmic research, earning her recognition among peers in the global vision science community.

Research Focus 

Dr. Aiyin Chen research focuses on advancing glaucoma detection, risk prediction, and disease management through technology-driven approaches. Her work includes developing machine learning models to predict glaucoma onset and progression, exploring the use of optical coherence tomography angiography for early diagnosis, and designing telemedicine-based screening strategies for underserved areas. She has contributed to studies evaluating clinic efficiency through data modeling and examined ocular blood flow in glaucoma patients before and after surgical interventions. With a strong record of NIH-funded research, Dr. Chen’s efforts aim to integrate imaging, big data analytics, and community outreach to improve glaucoma care worldwide.

Publication Top Notes

Does in vitro susceptibility predict clinical outcome in bacterial keratitis?

Measuring glaucomatous focal perfusion loss in the peripapillary retina using OCT angiography

Semaglutide and nonarteritic anterior ischemic optic neuropathy

Scleral intraocular pressure measurement in cadaver eyes pre-and postkeratoprosthesis implantation

Patterns of neural activation associated with exposure to odors from a familiar winner in male golden hamsters

Asian herbal-tobacco cigarettes:“not medicine but less harmful”?

Effect of algorithms and covariates in glaucoma diagnosis with optical coherence tomography angiography

Focal loss analysis of nerve fiber layer reflectance for glaucoma diagnosis

Prediction of multiclass surgical outcomes in glaucoma using multimodal deep learning based on free-text operative notes and structured EHR data

Extraction of active medications and adherence using natural language processing for glaucoma patients

Integrating deep learning with electronic health records for early glaucoma detection: a multi-dimensional machine learning approach

Emerging frontline leaders’ voices in response to COVID-19 crisis

Surgical management of an optic nerve glioma with perineural arachnoidal gliomatosis growth pattern

Optical coherence tomographic angiography detects retinal vascular changes associated with pituitary adenoma

Subrata Kar | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Subrata Kar | Clinical Trials | Best Researcher Award

Subrata Kar at Virginia Commonwealth University | United States

Dr. Subrata Kar is a distinguished interventional cardiologist and academic leader currently serving as Associate Professor of Medicine at Virginia Commonwealth University and Interventional Cardiologist at the Veterans Affairs Medical Center in Richmond, Virginia. With specialization in structural heart disease, peripheral vascular intervention, and advanced heart failure and transplant cardiology, Dr. Kar has held leadership roles at multiple prestigious institutions including UCLA, Texas Tech University, and NYC Health + Hospitals. He has been instrumental in launching advanced cardiology programs, mentoring trainees, and leading clinical and academic departments. His work reflects a deep commitment to patient care, education, and cardiovascular innovation.

Publication Profile 

Orcid

Education 

Dr. Kar earned his Doctor of Osteopathic Medicine from the New York College of Osteopathic Medicine, where he also completed a Neuroanatomy Fellowship. He holds dual bachelor’s degrees in Bio-Mathematics and Biology from Rutgers University. His post-graduate training includes an internal medicine residency at the Cleveland Clinic, followed by a cardiovascular medicine fellowship at the University of Missouri-Columbia. He further specialized with interventional cardiology fellowships at Stony Brook University and UCLA, where he also trained in structural and congenital heart disease. Additionally, he completed an advanced heart failure and transplant cardiology fellowship at NYU Langone Medical Center.

Experience 

Dr. Kar has served in diverse clinical, academic, and leadership roles across major medical institutions in the U.S. Currently an Interventional Cardiologist and Advanced Heart Failure specialist at VCU/VA Medical Center, he previously held senior positions at Middletown Medical, NYC Health + Hospitals, Texas Tech University, and UCLA. His roles have included Division Chief, Director of Interventional Cardiology, and Chair of Fellowship Selection Committees. He has also worked as a hospitalist at the Cleveland Clinic and a clinical instructor at UCLA. His experience reflects comprehensive expertise in interventional cardiology, structural heart interventions, and academic program development.

Awards and Honors 

Dr. Kar has received recognition for both clinical excellence and academic leadership. At UCLA and Texas Tech, he was instrumental in program development and fellowship training, earning him leadership roles such as Chair of the Academic Cardiology Section of the American College of Cardiology (Texas Chapter). He has been invited to present at national cardiology conferences and served on key committees evaluating trainee competency. His pioneering clinical program launches, particularly in interventional cardiology at Coney Island Hospital, highlight his innovation and impact. His mentorship and contributions to cardiology education have also been widely commended by academic and hospital leadership.

Research Focus 

Dr. Kar’s research centers on structural heart disease, adult congenital heart defects, interventional cardiology techniques, and advanced heart failure therapies. He has explored minimally invasive cardiovascular interventions, radiation reduction in catheterization procedures (KAR RAD study), and cardiac CT applications. He has presented nationally on outcomes in percutaneous valve procedures and congenital heart disease management. His work also includes developing safety protocols and training programs in cardiac catheterization labs. Through his research, he integrates clinical innovation with academic insight, advancing cardiovascular treatment and education, especially in underserved populations. His mentoring of trainees in research further amplifies his academic reach.

Publication Top Notes

Application and Outcomes of Minimal-Dose Versus Standard-Dose Radiation in Peripheral Endovascular Intervention (KAR Endovascular Study)

Meixian Zhang | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Meixian Zhang | Clinical Trials | Best Researcher Award

Director at Taizhou Hospital of Zhejiang Province | China

Dr. Meixian Zhang is an Associate Researcher and Master’s Supervisor at Wenzhou Medical University. With a Ph.D. in Public Health, she specializes in clinical epidemiology, evidence-based medicine, and obesity research. Her career is marked by over 35 SCI journal publications and leadership in multiple national and provincial research projects. She is deeply committed to tackling childhood obesity through genetic and dietary studies. With a passion for translational health research and mentoring, Dr. Zhang has earned recognition through innovation, impactful findings, and dedicated academic service. She continues to push boundaries in the fight against obesity-related health risks.

Publication Profile 

Orcid

Education

Dr. Zhang Meixian earned her Ph.D. in Public Health, specializing in childhood obesity and molecular epidemiology. Her academic journey began with a strong foundation in clinical medicine and public health, followed by doctoral research focusing on genetic predisposition to pediatric adiposity. She has been trained extensively in clinical epidemiology, biostatistics, and molecular genetics. Her postgraduate training enabled her to explore multifaceted aspects of obesity-related metabolic disorders and the implementation of evidence-based interventions. The academic rigor and scientific integrity developed during her education continue to guide her ongoing contributions to translational research and public health education.

Experience

With over a decade of research and academic experience, Dr. Zhang currently serves as an Associate Researcher at Wenzhou Medical University. She has supervised graduate students and led numerous scientific projects as principal investigator. Her work bridges molecular epidemiology, public health policy, and clinical research. She’s received major grants from the National Natural Science Youth Fund and Zhejiang provincial programs. She has also contributed to high-impact studies on obesity, SNPs, and weight management. Through editorial appointments and cross-institution collaborations, she continues to expand the reach of her research across China and the global scientific community.

Awards 

Dr. Zhang has received significant recognition for her contributions to medical research. She has been awarded grants from the National Natural Science Youth Fund and the Basic Public Welfare Research Program of Zhejiang Province as a Principal Investigator. Additionally, she has secured two provincial-level medical and science grants and one from the Taizhou Science and Technology Council. Her innovative research has led to two authorized national invention patents and one software copyright. These accolades underscore her scientific excellence and translational impact in obesity and metabolic health, positioning her as a leading figure in evidence-based public health research.

Research Focus 

Dr. Zhang’s research centers on childhood obesity, metabolic syndrome, and genetic susceptibility markers. She investigates the role of leptin, adiponectin, FTO gene variants, and other biomarkers in the development of obesity. Her work bridges molecular epidemiology with clinical nutrition, validating interventions such as intermittent fasting, calorie restriction, and meal replacements. Additionally, she explores single-nucleotide polymorphisms (SNPs) and their regulatory functions in metabolic pathways. Dr. Zhang’s interdisciplinary approach integrates public health, genomics, and preventive medicine, aiming to deliver targeted health strategies for pediatric populations in China and globally.

Top Publications

Title: Willingness of Older Adults with Chronic Diseases to Receive a Booster Dose of Inactivated Coronavirus Disease 2019 Vaccine: A Cross-Sectional Study in Taizhou
Year: 2025

Conclusion

Dr. Zhang Meixian’s academic rigor, originality, and focused contributions in combating obesity through evidence-based and genetics-informed approaches position her as an outstanding candidate for the Best Researcher Award. Her ability to translate complex research into meaningful public health solutions, combined with her strong record of funding, publications, and innovation, make her a worthy and impactful recipient of this recognition. With minor strategic advancements, her global influence is poised to grow even further.

Dr. Minoo Moghimi|Clinical Trials|Best Researcher Award

Published on by Top Pharmaceutical

Dr. Minoo Moghimi|Clinical Trials|Best Researcher Award

Dr. Minoo Moghimi at Mazandaran University of Medical Sciences,Iran

PROFILE  

Google scholar

 

Early Academic Pursuits 🎓

Minoo Moghimi embarked on her academic journey with a solid foundation in the National Organization for Development of Exceptional Talents, where she obtained her high school diploma in Yazd (2007-2011). This formative education laid the groundwork for her entrance into the field of pharmacy, where she pursued a PharmD at Yazd University of Medical Sciences from 2011 to 2018. Her early involvement with the faculty research committee highlighted her dedication to the field of pharmacotherapy, showcasing a keen interest in advancing pharmaceutical science right from the start.

Moghimi’s PharmD thesis focused on developing porous microencapsulated probiotics using a spray freeze drying technique. This innovative research emphasized the importance of drug formulation technology and aimed at enhancing probiotic viability. The success of this project led to a patent, marking a significant achievement in her early career and reflecting her capability to contribute meaningfully to pharmaceutical innovation.

Professional Endeavors 🏥

After completing her PharmD, Moghimi chose to channel her expertise into clinical applications by entering the Clinical Pharmacy Residency Program at Mazandaran University of Medical Sciences in 2018. This decision was driven by her passion for directly assessing drug effects in real-world patient scenarios. Throughout her residency, she demonstrated a profound dedication to clinical pharmacy, actively participating in research programs and engaging in numerous projects with a strong focus on clinical trials.

Her professional trajectory took a pivotal turn in 2020 during the COVID-19 pandemic when she contributed to the DISCOVER trial. This was a large-scale, randomized clinical trial involving over 1,000 patients, evaluating the efficacy of sofosbuvir and daclatasvir in treating hospitalized COVID-19 patients. The findings, published in the Journal of Antimicrobial Chemotherapy, were instrumental in understanding potential treatment options during the pandemic, reflecting her commitment to evidence-based clinical practice.

Moghimi’s professional expertise also extends beyond infectious diseases, as she has been involved in designing and implementing clinical trials in oncology, gynecology, and dentistry. Her diverse research portfolio underscores her adaptability and readiness to tackle multifaceted clinical challenges.

Contributions and Research Focus 📚

Minoo Moghimi’s primary research focus lies in managing chemotherapy-induced adverse effects, a critical area that significantly impacts cancer patient care. Her ongoing residency thesis, “Evaluation of the Efficacy and Safety of the Addition of Lacosamide to Duloxetine in the Treatment of Taxane-Induced Peripheral Neuropathy: A Randomized Double-Blind Placebo-Controlled Trial,” reflects this focus. Through this project, she aims to mitigate the debilitating side effects associated with chemotherapy, thus enhancing the quality of life for cancer patients.

In addition to her research in oncology, Moghimi has actively contributed to pharmacotherapy in critical care settings, clinical nutrition management, and drug-drug interaction management. Her ability to design comprehensive clinical trials is supported by her skills in clinical trial design, protocol development for critical medications, and medication reconciliation—skills that have proven vital in her multidisciplinary approach to patient care.

Moghimi’s contributions are not limited to clinical environments; she also engages in academic service. As a reviewer for respected journals like Pharmaceutical and Biomedical Research Journal (PBR) and Annals of Clinical and Medical Case Reports, she evaluates research, ensuring high standards in pharmacotherapy literature.

Accolades and Recognition 🏅

Throughout her academic and professional career, Minoo Moghimi has achieved several notable milestones. Her early achievement in patenting her thesis project during her PharmD studies reflects her commitment to innovation. During the COVID-19 pandemic, her role in the DISCOVER trial received significant recognition, as the study’s outcomes played a crucial role in informing clinical practices and treatment protocols for COVID-19 patients.

Impact and Influence 🌍

Minoo Moghimi’s research has had a tangible impact on the fields of clinical pharmacy and pharmacotherapy. Her work in chemotherapy-induced adverse effects, particularly taxane-induced peripheral neuropathy, aims to provide oncologists with better tools to manage the side effects of cancer treatments. By focusing on this critical aspect of cancer care, she is not only advancing research but also directly contributing to patient well-being, showcasing the transformative power of targeted pharmacotherapy.

Her involvement in critical care pharmacotherapy, nutrition management, and drug-drug interaction management demonstrates a holistic approach to patient care, where she considers various factors influencing therapeutic outcomes. This multidisciplinary expertise positions her as a key contributor to advancing patient-centered care in clinical settings.

Legacy and Future Contributions 🌟

Looking ahead, Minoo Moghimi aims to continue her work at the intersection of research and clinical practice. Her focus on chemotherapy-induced adverse effects, critical care, and nutrition management indicates a commitment to advancing patient care through evidence-based research. As a Board Certified Pharmacotherapy Specialist, her goal is to bridge the gap between research and clinical applications, ensuring that pharmacotherapy evolves in response to patient needs.

In the future, Moghimi plans to expand her research into novel drug therapies, aiming to develop innovative interventions for managing complex clinical conditions. Her dedication to the peer-review process reflects her intention to contribute to the scientific community by ensuring the dissemination of accurate and impactful research findings.

Skills and Technological Expertise 💻

Minoo Moghimi possesses a diverse skill set encompassing clinical trial design, research management, and critical care pharmacotherapy. Her expertise extends to protocol development for high-risk drugs, clinical nutrition, and drug-drug interaction management. In terms of technical skills, she is proficient with software like GraphPad Prism, Endnote, and MS Office—tools that are essential for managing data, conducting statistical analysis, and organizing research findings.

Research Interests and Aspirations 🔬

Her primary research interests revolve around chemotherapy-induced adverse effects, a field that holds immense potential for improving cancer care outcomes. Moghimi is also dedicated to critical care pharmacotherapy and nutrition management, fields where she hopes to make significant contributions in the future. Her aspiration is to develop strategies and guidelines that healthcare professionals can utilize to optimize treatment outcomes in complex clinical scenarios.

Conclusion 🎯

Minoo Moghimi’s journey from a dedicated pharmacy student to a Board Certified Pharmacotherapy Specialist is marked by a strong academic foundation, substantial research contributions, and a commitment to improving patient care. Her work has already left an indelible mark on the clinical pharmacy landscape, and her ongoing projects promise to further enhance therapeutic approaches in critical care and oncology. Moghimi’s career is a testament to the profound impact that dedicated research, clinical expertise, and a patient-centered approach can have in advancing healthcare.

🎓Publication 

A Narrative Review on Adverse Effects of Dasatinib With a Focus on Pharmacotherapy of Dasatinib-Induced Pulmonary Toxicities

  • Authors   :Zahra Nekoukar, Minoo Moghimi, Ebrahim Salehifar
  • Journal    :Blood Research
  • Year         :2021

Evaluation of the Effect of Sofosbuvir and Daclatasvir in Hospitalised COVID-19 Patients: A Randomized Double-Blind Clinical Trial (DISCOVER)

  • Authors   : Sara Mobarak, Mehdi Salasi, Ahmad Hormati, Javad Khodadadi, Masood Ziaee, Farshid Abedi, Azadeh Ebrahimzadeh, Zohreh Azarkar, Fariborz Mansour-Ghanaei, Farahnaz Joukar, Sara Yeganeh, Tofigh Yaghubi Kalurazi, Mohammadreza Naghipour, Zeinab Mehrabi, Amir Reza Bahadori, Shoeleh Yaghoubi, Rohollah Moslemi, Hamideh Abbaspour Kasgari, Hafez Fakheri, Minoo Moghimi, Amir Mohammad Shabani, Zahra Nekoukar, Farhang Babamahmoodi, 
  • Year         :2025

Comparison of the Efficacy and Safety of Atazanavir/Ritonavir Plus Hydroxychloroquine with Lopinavir/Ritonavir Plus Hydroxychloroquine in Patients with moderate COVID-19, A

  • Authors   :Zahra Nekoukar , Shahram Ala, Siavash Moradi, Andrew Hill, Ali Reza Davoudi Badabi, Ahmad Alikhani, Shahriar Alian, Minoo Moghimi, Amir Mohammad Shabani, Hamideh Abbaspour Kasgari
  • Journal    :Iranian Journal of Pharmaceutical Research
  • Year         :2021

Suicide attempt using zinc phosphide rodenticide: A case report and literature review

  • Authors   :Zahra Nekoukar, Minoo Moghimi, Kimia Rasouli, Aref Hoseini, Zakaria Zakariaei, Rabeeh Tabaripour, Mahdi Fakhar, Elham Sadat Banimostafavi 
  • Journal    : Clinical case reports
  • Year         :2021

Prevalence of Thromboembolic Events, Including Venous Thromboembolism and Arterial Thrombosis, in Patients with COVID-19: A Systematic Review with Meta-Analysis

  • Authors   :Babak Bagheri, Abbas Alipour, Mojtaba Yousefi, Rozita Jalalian, Minoo Moghimi, Mahsa Mohammadi, Negar Hassanpour, Mohammadreza Iranian
  • Journal    :Tehran University of Medical Sciences
  • Year         :2023